Holistic approach to methotrexate treatment in rheumatology and dermatology Review article
Article Sidebar
Published:
Sep 30, 2022
Keywords:
rheumatoid arthritis, psoriasis, psoriatic arthritis, methotrexate, oral, subcutaneous
Main Article Content
Abstract
Oral or subcutaneous methotrexate is registered, inter alia, in the treatment of rheumatoid arthritis, psoriasis and psoriatic arthritis. The choice of form should be based on an analysis of the patient’s needs and condition as well as the pharmacological properties of the given form. The paper presents the differences between the oral form and the subcutaneous form of methotrexate.
Article Details
How to Cite
Kwiatkowska, B. (2022). Holistic approach to methotrexate treatment in rheumatology and dermatology. Medycyna Faktow (J EBM), 15(3(56), 293-296. https://doi.org/10.24292/01.MF.0322.3
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Cronstein BN, Thomas MA. Methotrexate and its mechanisms of action in inflammatory arthritis. Nature Review Rheumatology. 2020; 16: 145-54.
2. Coates LC, Helliwell PS. Methotrexate efficacy in the tight control in psoriatic arthritis study. J Rheumatol. 2016; 43: 356-61.
3. Smolen JS, Landewé R BM, Bijlsma WJ et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020; 79: 685-99.
4. Coates LC, Helliwell S. Methotrexate efficacy in the Tight Control in Psoriatic arthritis (TICOPA) study. J Rheumatol. 2016; 43(2): 356-61.
5. Merola JF, Ogdie A. SEAM-PsA: Seems like methotrexate works in Psoriatic Arthritis? Arthritis Rheumatol. 2019; 71(7): 1027-9.
6. Coates LC, Soriano E, Corp N et al. The Group For Research And Assessment Of Psoriasis And Psoriatic Arthritis (GRAPPA) treatment recommendations 2021. Ann Rheum Dis. 2021; 10.1136/annrheumdis-2021-eular.4091.
7. Smolen JS, Landewé RBM, Bijlsma JWJ et al. EULAR recommendations for the managememnt of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020; 79: 685-99.
8. Generali E, Carrara G, Bortoluzzi A et al. Non-adherence and discontinuation rate for oral and parenteral methotrexate: A retrospective-cohort study in 8,952 patients with psoriatic arthritis. J Transl Autoimmun. 2021; 4: 100113.
9. Christien KHL, Baker K, Jones T et al. Safety and Tolerability of Subcutaneous Methotrexate in Routine Clinical Practice. Arthritis Care Res. 2020. http://doi.org/10.1002/acr.24334.
10. Herman RA, Veng-Pedersen P, Hoffman J et al. Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. J Pharm Sci. 1989; 78(2): 165-71.
11. Murakami T, Mori N. Involvement of multiple transporters-mediated transports in mozoribine and methotrexate pharmacokinetics. Pharmaceuticals (Basel). 2012; 5: 812.
12. Bello AE, Perkins EL, Jay R et al. Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis. Open Access Rheumatology. Research and Reviews 2017; 9: 67-79 za Pichlmeier U, Heuer KU. Clin Exp Rheumatol. 2014; 32(4): 563-71.
13. O’Connor A, Thorne C, Kang H et al. The rapid kinetics of optimal treatment with subcutaneus methotrexate in early inflammatory arthritis: an observational study. BMC. Musculoskeletal Disord. 2016; 17(1): 364.
14. Bujor AM, Janjua S, LaValley MP et al. Comparison of oral versus parenteral methotrexate in the treatment of rheumatoid arthritis: A meta-analysis. PLOSE ONE. 2019; 14(9): e0221823.
15. Braun J, Kästner P, Flaxenberg P et al. Comparison of the Clinical Efficacy and Safety of Subcutaneous Versus Oral Administration of Methotrexate in Patients With Active Rheumatoid Arthritis. Results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008; 58: 73-81.
16. Christen KH Li, Baker K, Jones T et al. Safety and Tolerability of Subcutaneous Methotrexate in Routine Clinical Practice. Arthritis Care Res. 2021; 73(9): 1306-11.
17. Kromann CB, Lage-Hansen PR, Koefoed M et al. Does switching from oral to subcutaneous administration of methotrexate influence on patient reported gastro-intestinal adverse effects? J Dermatol Treat. 2015; 26(2): 188-90. http://doi.org/10.3109/09546634.2014.927817.
18. Dervieux T, Zablocki R, Kremer J. Red Blood Cell Methotrexate Polyglutamates Emerge as a Function of Dosage Intensity and Route of Administration During Pulse Metho trexate Therapy in Rheumatoid Arthritis. Rheumatology 2010; 49: 2337-45.
19. Senbel E, Tropé S, Herman-Demars H et al. Benefits of Switch from Oral to Subcutaneous Route on Adherence to Methotrexate in Patients with Rheumatoid Arthritis in Real Life Setting. Patient Prefer Adherence. 2021; 15: 751-60.
2. Coates LC, Helliwell PS. Methotrexate efficacy in the tight control in psoriatic arthritis study. J Rheumatol. 2016; 43: 356-61.
3. Smolen JS, Landewé R BM, Bijlsma WJ et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020; 79: 685-99.
4. Coates LC, Helliwell S. Methotrexate efficacy in the Tight Control in Psoriatic arthritis (TICOPA) study. J Rheumatol. 2016; 43(2): 356-61.
5. Merola JF, Ogdie A. SEAM-PsA: Seems like methotrexate works in Psoriatic Arthritis? Arthritis Rheumatol. 2019; 71(7): 1027-9.
6. Coates LC, Soriano E, Corp N et al. The Group For Research And Assessment Of Psoriasis And Psoriatic Arthritis (GRAPPA) treatment recommendations 2021. Ann Rheum Dis. 2021; 10.1136/annrheumdis-2021-eular.4091.
7. Smolen JS, Landewé RBM, Bijlsma JWJ et al. EULAR recommendations for the managememnt of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020; 79: 685-99.
8. Generali E, Carrara G, Bortoluzzi A et al. Non-adherence and discontinuation rate for oral and parenteral methotrexate: A retrospective-cohort study in 8,952 patients with psoriatic arthritis. J Transl Autoimmun. 2021; 4: 100113.
9. Christien KHL, Baker K, Jones T et al. Safety and Tolerability of Subcutaneous Methotrexate in Routine Clinical Practice. Arthritis Care Res. 2020. http://doi.org/10.1002/acr.24334.
10. Herman RA, Veng-Pedersen P, Hoffman J et al. Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. J Pharm Sci. 1989; 78(2): 165-71.
11. Murakami T, Mori N. Involvement of multiple transporters-mediated transports in mozoribine and methotrexate pharmacokinetics. Pharmaceuticals (Basel). 2012; 5: 812.
12. Bello AE, Perkins EL, Jay R et al. Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis. Open Access Rheumatology. Research and Reviews 2017; 9: 67-79 za Pichlmeier U, Heuer KU. Clin Exp Rheumatol. 2014; 32(4): 563-71.
13. O’Connor A, Thorne C, Kang H et al. The rapid kinetics of optimal treatment with subcutaneus methotrexate in early inflammatory arthritis: an observational study. BMC. Musculoskeletal Disord. 2016; 17(1): 364.
14. Bujor AM, Janjua S, LaValley MP et al. Comparison of oral versus parenteral methotrexate in the treatment of rheumatoid arthritis: A meta-analysis. PLOSE ONE. 2019; 14(9): e0221823.
15. Braun J, Kästner P, Flaxenberg P et al. Comparison of the Clinical Efficacy and Safety of Subcutaneous Versus Oral Administration of Methotrexate in Patients With Active Rheumatoid Arthritis. Results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008; 58: 73-81.
16. Christen KH Li, Baker K, Jones T et al. Safety and Tolerability of Subcutaneous Methotrexate in Routine Clinical Practice. Arthritis Care Res. 2021; 73(9): 1306-11.
17. Kromann CB, Lage-Hansen PR, Koefoed M et al. Does switching from oral to subcutaneous administration of methotrexate influence on patient reported gastro-intestinal adverse effects? J Dermatol Treat. 2015; 26(2): 188-90. http://doi.org/10.3109/09546634.2014.927817.
18. Dervieux T, Zablocki R, Kremer J. Red Blood Cell Methotrexate Polyglutamates Emerge as a Function of Dosage Intensity and Route of Administration During Pulse Metho trexate Therapy in Rheumatoid Arthritis. Rheumatology 2010; 49: 2337-45.
19. Senbel E, Tropé S, Herman-Demars H et al. Benefits of Switch from Oral to Subcutaneous Route on Adherence to Methotrexate in Patients with Rheumatoid Arthritis in Real Life Setting. Patient Prefer Adherence. 2021; 15: 751-60.